vs
Side-by-side financial comparison of CPI AEROSTRUCTURES INC (CVU) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
CPI AEROSTRUCTURES INC is the larger business by last-quarter revenue ($19.4M vs $16.1M, roughly 1.2× Journey Medical Corp). CPI AEROSTRUCTURES INC runs the higher net margin — 3.6% vs -7.8%, a 11.3% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -10.8%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 0.9%).
CPI Aerostructures Inc., known as CPI Aero, is a contract aircraft component manufacturer based in Edgewood, New York.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
CVU vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.4M | $16.1M |
| Net Profit | $691.8K | $-1.2M |
| Gross Margin | 20.3% | — |
| Operating Margin | 6.4% | -2.8% |
| Net Margin | 3.6% | -7.8% |
| Revenue YoY | -10.8% | 27.3% |
| Net Profit YoY | -28.8% | -182.0% |
| EPS (diluted) | $0.04 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.4M | $16.1M | ||
| Q3 25 | $19.3M | $17.0M | ||
| Q2 25 | $15.2M | $15.0M | ||
| Q1 25 | $15.4M | $13.1M | ||
| Q4 24 | $21.8M | $12.6M | ||
| Q3 24 | $19.4M | $14.6M | ||
| Q2 24 | $20.8M | $14.9M | ||
| Q1 24 | $19.1M | $13.0M |
| Q4 25 | $691.8K | $-1.2M | ||
| Q3 25 | $1.1M | $-2.3M | ||
| Q2 25 | $-1.3M | $-3.8M | ||
| Q1 25 | $-1.3M | $-4.1M | ||
| Q4 24 | $971.5K | $1.5M | ||
| Q3 24 | $749.7K | $-2.4M | ||
| Q2 24 | $1.4M | $-3.4M | ||
| Q1 24 | $168.2K | $-10.4M |
| Q4 25 | 20.3% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 4.4% | — | ||
| Q1 25 | 10.7% | — | ||
| Q4 24 | 20.0% | 82.3% | ||
| Q3 24 | 21.7% | 63.9% | ||
| Q2 24 | 24.6% | 56.0% | ||
| Q1 24 | 18.6% | 47.7% |
| Q4 25 | 6.4% | -2.8% | ||
| Q3 25 | 9.1% | -9.0% | ||
| Q2 25 | -13.1% | -19.2% | ||
| Q1 25 | -7.7% | -25.3% | ||
| Q4 24 | 9.5% | 17.7% | ||
| Q3 24 | 7.6% | -19.8% | ||
| Q2 24 | 11.2% | -19.7% | ||
| Q1 24 | 4.4% | -77.4% |
| Q4 25 | 3.6% | -7.8% | ||
| Q3 25 | 5.8% | -13.6% | ||
| Q2 25 | -8.7% | -25.3% | ||
| Q1 25 | -8.6% | -31.0% | ||
| Q4 24 | 4.5% | 12.1% | ||
| Q3 24 | 3.9% | -16.3% | ||
| Q2 24 | 6.8% | -22.6% | ||
| Q1 24 | 0.9% | -80.1% |
| Q4 25 | $0.04 | $-0.04 | ||
| Q3 25 | $0.09 | $-0.09 | ||
| Q2 25 | $-0.10 | $-0.16 | ||
| Q1 25 | $-0.10 | $-0.18 | ||
| Q4 24 | $0.08 | $0.10 | ||
| Q3 24 | $0.06 | $-0.12 | ||
| Q2 24 | $0.11 | $-0.17 | ||
| Q1 24 | $0.01 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $24.1M |
| Total DebtLower is stronger | $0 | $25.3M |
| Stockholders' EquityBook value | $25.8M | $31.9M |
| Total Assets | $75.2M | $94.6M |
| Debt / EquityLower = less leverage | 0.00× | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.1M | ||
| Q3 25 | — | $24.9M | ||
| Q2 25 | — | $20.3M | ||
| Q1 25 | — | $21.1M | ||
| Q4 24 | — | $20.3M | ||
| Q3 24 | — | $22.5M | ||
| Q2 24 | — | $23.9M | ||
| Q1 24 | — | $24.1M |
| Q4 25 | $0 | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | $26.5K | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $25.8M | $31.9M | ||
| Q3 25 | $25.0M | $25.9M | ||
| Q2 25 | $23.8M | $19.2M | ||
| Q1 25 | $24.9M | $21.5M | ||
| Q4 24 | $25.9M | $20.1M | ||
| Q3 24 | $24.9M | $10.9M | ||
| Q2 24 | $24.1M | $11.3M | ||
| Q1 24 | $22.5M | $13.0M |
| Q4 25 | $75.2M | $94.6M | ||
| Q3 25 | $74.1M | $85.2M | ||
| Q2 25 | $72.3M | $81.2M | ||
| Q1 25 | $65.4M | $85.0M | ||
| Q4 24 | $68.0M | $80.2M | ||
| Q3 24 | $68.9M | $64.0M | ||
| Q2 24 | $70.2M | $65.2M | ||
| Q1 24 | $70.8M | $66.6M |
| Q4 25 | 0.00× | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | 0.00× | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.1M | $-6.3M |
| Free Cash FlowOCF − Capex | $-2.1M | — |
| FCF MarginFCF / Revenue | -10.8% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -3.03× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-5.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.1M | $-6.3M | ||
| Q3 25 | $212.1K | $-2.4M | ||
| Q2 25 | $-596.3K | $-942.0K | ||
| Q1 25 | $-2.7M | $-2.8M | ||
| Q4 24 | $4.4M | $2.2M | ||
| Q3 24 | $715.1K | $-1.2M | ||
| Q2 24 | $-591.7K | $-5.2M | ||
| Q1 24 | $-960.5K | $-5.0M |
| Q4 25 | $-2.1M | — | ||
| Q3 25 | $211.1K | — | ||
| Q2 25 | $-599.8K | — | ||
| Q1 25 | $-2.8M | — | ||
| Q4 24 | $4.3M | — | ||
| Q3 24 | $586.9K | — | ||
| Q2 24 | $-746.9K | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -10.8% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | -4.0% | — | ||
| Q1 25 | -18.1% | — | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | -3.6% | — | ||
| Q1 24 | -5.3% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | -3.03× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4.53× | 1.46× | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.42× | — | ||
| Q1 24 | -5.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVU
| Government Subcontracts | $16.4M | 85% |
| Commercial Contracts | $2.3M | 12% |
| Prime Government Contracts | $725.8K | 4% |
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
